Loading...

iBio, Inc.

IBIO•NASDAQ
Healthcare
Biotechnology
$0.76
$0.05(6.34%)

iBio, Inc. (IBIO) Stock Overview

Explore iBio, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 66.6/100

Key Financials

Market Cap12.2M
P/E Ratio-0.34
EPS (TTM)$-0.04
ROE-1.30%

AI Price Forecasts

1 Week$0.87
1 Month$0.51
3 Months$23.46
1 Year Target$1.41

IBIO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of iBio, Inc. (IBIO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $1.41.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.34 and a market capitalization of 12.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
0.00%
Profit Growth
$-2.13
↑ 15.03%
EPS Growth
$-2.13
↑ 72.85%
Operating Margin
-4483.47%
↑ 43.25%
ROE
-130.48%
↑ 15.03%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
Buy
Hold
Sell
Strong Sell

Price Targets

Low$3.60
Average$3.60
High$3.60

Company Profile

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

CEO

Dr. Martin B. Brenner D.V.M., Ph.D.

Employees

16

Headquarters

8800 HSC Parkway, Bryan, TX

Founded

2008

Frequently Asked Questions

;